Jan 10, 2024 / 05:45PM GMT
Tess Romero JPMorgan Chase&Co.-Analyst
Welcome everyone to the 42nd annual JP Morgan Healthcare Conference. My name is Tess Romero, and I am one of the senior biotech analysts here at JPMorgan. Our next presenting company is Seres Therapeutics and presenting on behalf of the company. We have CEO Eric Shaff. Eric?
Eric Shaff Seres Therapeutics - Inc. - President & CEO
Well, thank you, Tess, and thanks to JPMorgan for having us here today. It's great to be in person with you this morning at JPMorgan and have the opportunity to connect. And together, I'm joined with my team, David Terri, Matt, and Rob, and we're thrilled to be here to talk about Seres and answer your questions following a short presentation. So I will be making forward-looking statements in this presentation. So as usual, I encourage you to review our Safe Harbor statement and risk factors in our last 10-Q.
So excited to start this morning with a discussion around two key updates that we are pleased to share. The first is preliminary Q4 commercial results
Seres Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers